Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Published 12 Jun 2019

Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 22 – 26, 2019 in Anaheim, Ca. Highlighted presentations encompass clinical use of Axumin® (fluciclovine F 18) injection; investigational use of 18F-fluciclovine; and initial clinical experience by the Technical University of Munich with 18F-rhPSMA-7, an investigational Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging agent representative of the family of rhPSMA agents that Blue Earth Diagnostics exclusively licensed in 2018.

Senior executives from Blue Earth Diagnostics will participate in sessions about advancing companies from concept to commercialization, and current and future approaches to molecular imaging and therapy. In addition, a special program led by SNMMI, “Fluciclovine Live Reader Training,” will be held immediately prior to the Annual Meeting. Details of selected oral and poster presentations by Blue Earth Diagnostics and its collaborators are listed below.

NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by “*” discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use or purpose noted, or “*” denotes experience with an investigational agent for which the safety and efficacy have not been established by the FDA.

HIGHLIGHTED SCIENTIFIC PRESENTATIONS

 

Axumin (fluciclovine F 18) presentations

Date:                                   Monday, June 24, 2019

Poster Title:                       [18F]-fluciclovine positivity rate is not affected by androgen deprivation therapy (ADT) in recurrent prostate cancer post-prostatectomy

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          Olayinka Abiodun-Ojo, MD, Emory University

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1576

 

Date:                                   Monday, June 24, 2019

Poster Title:                       Comparison of 18F-Fluciclovine PET/CT and Technetium-99m MDP BS in Detection of Bone Metastasis in Prostate Cancer

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          Bo Chen, MD, MD Anderson Cancer Center

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1553

 

Investigational 18F-fluciclovine presentations

Date:                                   Monday, June 24, 2019

Session Title:                     SS47: Brain PET/MRI

Presentation Title:           Evaluation of glioma tumor volume with 18F-fluciclovine positron emission tomography interpreted in combination with MRI, compared with MRI alone: Results from a prospective phase 3 blinded image evaluation*

Presenter:                          Matthew P. Miller, PhD, Blue Earth Diagnostics

Session Time:                    4:45 – 6:15 PM PT

Presentation Time:          5:25 – 5:35 PM PT
Location:                            Room 204B

Publication No:                394

 

Date:                                   Tuesday, June 25, 2019

Session Title:                     SS58: Brain Imaging Reloaded II

Presentation Title:           Safety and effectiveness of 18F-fluciclovine PET in adults with recurrent glioma: A retrospective observational study*

Presenter:                       Tore Bach-Gansmo, MD, PhD, Oslo University Hospital

Session Time:                 10:00 – 11:30 AM PT

Presentation Time:          11:20 – 11:30 AM PT

Location:                        Room 201B

Publication No.                496

 

Date:                              Tuesday, June 25, 2019

Poster Title:                    PET imaging of recurrent brain tumors using 18F-FACBC*

Session Title:                  MTA II: Neurology & Psychiatry Imaging Posters

Presenter:                      Laure Michaud, MD, Memorial Sloan-Kettering Cancer Center

Presentation Time:          3:00 – 4:30 PM PT

Location:                        Exhibit Hall C

Publication No.:               1506

 

Date:                                Monday, June 24, 2019

Poster Title:                    [18F]-fluciclovine PET/CT is superior to conventional imaging in preoperative nodal staging in patients with high-risk prostate cancer*

Session Title:                  MTA I: Prostate/GU Imaging Posters

Presenter:                      Olayinka Abiodun-Ojo, MD, Emory University

Presentation Time:          3:00 – 4:30 PM PT

Location:                        Exhibit Hall C

Publication No.:               1580

 

Date:                                Monday, June 24, 2019

Poster Title:                      Preoperative staging in high-risk prostate cancer patients using [18F] fluciclovine PET/CT*

Session Title:                   MTA I: Prostate/GU Imaging Posters

Presenter:                       Akinyemi A. Akintayo, MD, Emory University

Presentation Time:          3:00 – 4:30 PM PT

Location:                        Exhibit Hall C

Publication No.:               1554

Date:                              Monday, June 24, 2019

Poster Title:                    [18F] Fluciclovine PET/MRI for Initial Staging of High-Risk Prostate Cancer*

Session Title:                  MTA I: Prostate/GU Imaging Posters

Presenter:                      Samuel J. Galgano, MD, University of Alabama at Birmingham

Presentation Time:          3:00 – 4:30 PM PT

Location:                        Exhibit Hall C

Publication No.:               1561

Date:                                 Tuesday, June 25, 2019

Poster Title:                       Using dynamic PET/CT imaging to explore the kinetics of 18F-fluciclovine (anti-(18)F-FACBC) in invasive breast cancer*

Session Title:                     MTA II: Data Analysis & Management Posters

Presenter:                          Nathaniel P. Scott, MSc, MPhys, University of Oxford

Presentation Time:              3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:                   1194

 

Date:                                   Tuesday, June 25, 2019

Session Title:                     SS65: Gynecological Cancers

Presentation Title:           Feasibility of Fluciclovine PET-CT Imaging of Endometrial, Cervical and Ovarian Cancers: Preliminary Findings*

Presenter:                          Funmilayo Tade, MD, MPH, Loyola University Medical Center

Session Time:                    12:30 – 2:00 PM PT

Presentation Time:          1:50 – 2:00 PM PT

Location:                            Room 202AB

Publication No.:               558

 

Presentations on initial clinical experience with 18F-rhPSMA-7 at Technical University of Munich

Date:                                   Monday, June 24, 2019

Poster Title:                       Preclinical dosimetry and human biodistribution of 18F-rhPSMA-7 and 18F-rhPSMA-7.3*

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          So Won Oh, MD, PhD, Seoul National University Boramae Hospital

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1635

 

Date:                                   Monday, June 24, 2019

Poster Title:                       Quantitative and qualitative analysis of biodistribution and PET image quality of novel radiohybrid PSMA ligand, 18F-rhPSMA-7, in patients with prostate cancer *

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          So Won Oh, MD, PhD, Seoul National University Boramae Hospital

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1557

 

Date:                                   Monday, June 24, 2019

Poster Title:                       Histologically-confirmed diagnostic efficacy of 18F-rhPSMA-7 positron emission tomography for N-staging of patients with high risk primary prostate cancer*

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          Markus Kroenke, Technical University of Munich

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1567

 

Date:                                   Tuesday, June 25, 2019

Session Title:                     SS69: Prostate Diagnosis I

Presentation Title:           18F-rhPSMA-7 positron emission tomography (PET) for the detection of biochemical recurrence of prostate cancer following curative-intent radiation therapy*

Presenter:                          Harun Ilhan, MD, Ludwig-Maximilian-University (LMU), Munich 

Session Time:                    12:30 – 2:00 PM PT

Presentation Time:          1:30 – 1:40 PM PT

Location:                            204B

Publication No.:               592

 

Date:                                   Tuesday, June 25, 2019

Session Title:                     SS76: Prostate Cancer Diagnosis II

Presentation Title:           18F-rhPSMA-7 positron emission tomography (PET) for the detection of biochemical recurrence of prostate cancer following radical prostatectomy*

Presenter:                          Matthias Eiber, MD, Technical University of Munich

Session Time:                    10:00 – 11:30 AM PT

Presentation Time:          11:20 11:30 AM PT

Location:                            Room 204B

Publication No.:               649

PANEL PRESENTATIONS

 

Date:                                   Saturday, June 22, 2019

Session Title:                     Concept to Commercialization and Funding Along the Way

Panel Title:                        Emerging Technologies, Funding, M&A

Panel Participant:             Jonathan Allis, D.Phil., CEO, Blue Earth Diagnostics

Session Time:                    Saturday 3:30 – 5

Location:                            Room 303AB

 

Date:                                   Sunday, June 23, 2019

Session Title:                     CMIIT Emerging Technologies – Emerging Technologies – A Look into the Future of Molecular Imaging and Therapy

Presentation Title:           Molecular Imaging and Therapy – Current and Future Approaches*

Presenter:                          David Gauden, D.Phil., CSO, Blue Earth Diagnostics

Session Time:                    4:30 – 6:00 PM PT

Presentation Time:          4:30 – 4:50 PM PT
Location:                            Room 201D

In addition, the following presentations will be part of independent continuing education programs at SNMMI.

 

Date:                                   Saturday, June 22, 2019

Session Title:                     SNMMI Special Programming

Presentation Title:           Fluciclovine Live Training Session

Session Time:                    9:00 AM PT – 12:00 PM PT

Location:                            Registration required: http://www.snmmi.org/AM/Registration/RegistrationAM.aspx

Date:                                   Saturday, June 22, 2019

Session Title:                     CE08: Prostate Cancer Nuts and Bolts: Diagnosis and Therapy

Presentation Title:           Prostate Cancer Diagnostic: Fluciclovine F18 PET/CT

Presenter:                          David M. Schuster, MD, Emory University

Session Time:                    3:15 – 4:45 PM PT

Presentation Time:          3:15 – 3:45 PM PT

Location:                            Room 211AB

Date:                                   Sunday, June 23, 2019

Session Title:                     CE29: New PET Radiopharmaceuticals – Read with the Experts

Presentation Title:           Fluciclovine F18 PET/CT

Presenter:                          David M. Schuster, MD, Emory University

Session Time:                    4:45 – 6:15 PM PT

Presentation Time:          4:45 – 5:05 PM PT

Location:                            Room 212AB

Blue Earth Diagnostics invites participants at this year’s SNMMI Annual Meeting to attend the presentations above and to visit the company at Exhibit Booth 720.